• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Sam­sung Bio eyes con­struc­tion of sixth man­u­fac­tur­ing plant to kick­start 2025

4 months ago
Manufacturing

Eli Lil­ly miss­es 2024 rev­enue ex­pec­ta­tions, stock dips 7%

4 months ago
Pharma
Manufacturing

HHS in­spec­tor gen­er­al rais­es con­cerns over three FDA ac­cel­er­at­ed ap­provals

4 months ago
FDA+

Lykos up­heaval con­tin­ues with four new board ex­its amid hunt for cash

4 months ago
People
Financing

Charles Riv­er dis­ap­points in­vestors with damp out­look for 2025

4 months ago
Manufacturing

Umo­ja’s $100M Se­ries C will ad­vance its bid for more con­ve­nient cell ther­a­pies

4 months ago
Financing
Cell/Gene Tx

Re­genxbio sells Hunter syn­drome li­cense with FDA fil­ing un­der­way

4 months ago
Deals

Aus­trali­a's BioCi­na and No­vaCi­na join forces to make one CD­MO

4 months ago
Deals
Manufacturing

Re­gen­eron, Il­lu­mi­na in­vest in Tru­ve­ta; In­hi­brx Bio’s $150M loan

4 months ago
News Briefing

FTC goes af­ter phar­ma mid­dle­men's price hikes on 'spe­cial­ty' drugs

4 months ago
Pharma
Law

Can the Pfiz­er ma­chine fight back against an ac­tivist in­vestor?

4 months ago
Pharma

Anavex re­ports long-term Alzheimer's da­ta for drug with his­to­ry of scruti­ny

4 months ago
R&D

The health­care com­pa­nies sit­ting out this year's JP Mor­gan Health­care Con­fer­ence

4 months ago
Health Tech

Ex­clu­sive: Day af­ter GSK buy­out, IDRx chair takes new in­vest­ing role at Curie.Bio

4 months ago
People
Startups

Dai­ichi Sankyo brings Gly­co­tope an­ti­body in-house for $132.5M

4 months ago
Deals
R&D

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

4 months ago
Pharma

Bio­haven’s pro­tein de­grad­er is promis­ing in ear­ly IgAN tri­al, heads straight to Phase 3

4 months ago
R&D

Health tech fund­ing in 2025 kicks off with megarounds

4 months ago
Financing
Health Tech

How a start­up is reimag­in­ing health in­sur­ance, as em­ploy­ers search for new op­tions

4 months ago
Health Tech

BIO CEO plans to join FDA mod­ern­iza­tion ad­vi­so­ry board un­der Trump ad­min­is­tra­tion

4 months ago
FDA+

Got­tlieb says RFK Jr. as HHS sec­re­tary could bring ‘trag­ic’ out­breaks

4 months ago
People
Pharma

Mod­er­na low­ers 2025 rev­enue es­ti­mate, an­nounces more cost cuts

4 months ago
Pharma
Coronavirus

Fed­er­al Cir­cuit up­holds No­var­tis patent for heart drug En­tresto

4 months ago
Pharma
Law

Ab­b­Vie part­ners with Sim­cere Phar­ma unit to de­vel­op myelo­ma drug

4 months ago
R&D
Pharma
First page Previous page 54555657585960 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times